GSK’s Strategic Focus and Recent Developments in 2026

As of June 9, 2026, pharmaceutical giant GSK (GSK Plc) continues to emphasize its commitment to innovation in key therapeutic areas, including respiratory, immunology, oncology, HIV, and infectious diseases. The company, which traces its origins to the 2000 merger of Glaxo and SmithKline, remains a pivotal player in global healthcare, with a mission to positively impact the health of 2.5 billion people by the end of the decade.

Recent Advances in Chronic Hepatitis B Treatment

GSK has highlighted breakthroughs in chronic hepatitis B (HBV) treatment, a condition affecting hundreds of millions globally. In a “Behind the Science” feature, the company shared the story of Natalia, a mother of two who navigates life with the virus. GSK’s efforts in this area align with its broader focus on infectious diseases, where it aims to address significant unmet medical needs.

Partnerships and Product Launches in China

In 2026, GSK has deepened its collaboration with Chinese biopharmaceutical company China Biopharmaceutical. This partnership accelerates the availability of bepirovirsen, a novel therapy for chronic HBV, in the Chinese market. Additionally, GSK has launched several innovative treatments in China, including 易适来® (Deucravacitinib) for asthma and nasal sinus conditions, and 倍乐锐® (Mabepirumab) for multiple myeloma. These developments underscore GSK’s commitment to expanding access to cutting-edge therapies in the region.

Focus on Oncology and Respiratory Health

GSK’s oncology portfolio remains a strategic priority, with ongoing research into targeted therapies. The company’s respiratory division addresses the global burden of lung diseases, which account for 7 million deaths annually. Recent approvals include a